Marc Talló-Parra
Chief Scientific Officer NoctuRNA Therapeutics
Marc Talló-Parra is the CSO and co-founder of noctuRNA Therapeutics S.L., a spin-off established based on the groundbreaking work from his PhD at the Universitat Pompeu Fabra. His research focused on the interplay between viral infections and circRNAs. This expertise culminated in developing an innovative, circRNA-based therapeutic platform. This technology targets and impairs the formation of aberrant secondary RNA structures critical for disease, demonstrating high efficiency against a range of viruses and genetic disorders.
Seminars
Thursday 28th May 2026
Panel: Contrasting Circular vs. Self-Amplifying RNA to Match Modalities to Use-Cases
9:00 am
- Weigh strengths and trade-offs in potency, durability, manufacturability, and safety to guide platform decisions
- Compare fit-for-purpose advantages across CAR-T, protein replacement, combination therapies, autoimmune, and CNS applications to reduce risk
- Define where each modality delivers a strategic edge and where constraints limit applicability for smarter portfolio planning
Thursday 28th May 2026
Engineering 300-nt Circular RNAs to Unfold Pathogenic RNA Structures as a Novel Therapeutic Strategy for Infectious & NonInfectious Diseases
3:00 pm
- Reverse structure-driven pathogenicity by applying hybridization-based circRNAs that block the formation of aberrant RNA structures underlying ALS, muscular dystrophies, and viral replication
- Expand circRNA utility well beyond vaccines and protein replacement by demonstrating a new non-canonical mode of action with in vitro and in vivo proof across multiple disease classes
- Strengthen translational readiness through insights into purity thresholds, linear– circular separation, and delivery considerations unique to small, non-coding circRNA modalities
